Will your super fund recover this year ask research teams

MELBOURNE: After one of the worst years for superannuation returns since the global ... read more

Two left in running for Healthscope hospital properties

MELBOURNE: The sale of a $1.2bn portfolio of Healthscope hospital properties is understood ... read more

Neuren drug finally been cleared by FDA in USA

SYDNEY: Australia’s top performing health stock for 2022, Neuren, has gained clearance from ... read more

Mesoblast shares surge on FDA filing in USA

SYDNEY: Mesoblast chief executive Silviu Itescu says a more than 12 per cent ... read more